Literature DB >> 9773726

Lactic acidosis rates in type 2 diabetes.

J B Brown1, K Pedula, J Barzilay, M K Herson, P Latare.   

Abstract

OBJECTIVE: To provide a context for the interpretation of lactic acidosis risk among patients using metformin, we measured rates of lactic acidosis in patients with type 2 diabetes before metformin was approved for use in the U.S. RESEARCH DESIGN AND METHODS: Using electronic databases of hospital discharge diagnoses and laboratory results maintained by a large, nonprofit health maintenance organization (HMO). we identified possible lactic acidosis events in three geographically and racially diverse populations with type 2 diabetes. We then reviewed hard-copy clinical records to confirm and describe each event and determine its likely cause(s).
RESULTS: From >41.000 person-years of experience, we found four confirmed, three possible, and three borderline cases of lactic acidosis. In each case, we identified at least one severe medical condition that could have caused the acidosis. The annual confirmed event rate is similar to published rates of metformin-associated lactic acidosis.
CONCLUSIONS: Lactic acidosis occurs regularly, although infrequently, among persons with type 2 diabetes, at rates similar to its occurrence among metformin users. The medical conditions with which both metformin-associated and naturally occurring lactic acidosis co-occur are also its potential causes. The observed association between metformin and lactic acidosis may be coincidental rather than causal. This possibility merits further study

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9773726     DOI: 10.2337/diacare.21.10.1659

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  45 in total

1.  Contraindications to the use of metformin.

Authors:  G C Jones; J P Macklin; W D Alexander
Journal:  BMJ       Date:  2003-01-04

2.  Clinical pharmacology physiology conference: metformin and lactic acidosis (LA).

Authors:  Chadi Alkhalil; George Zavros; Fadi Bailony; David T Lowenthal
Journal:  Int Urol Nephrol       Date:  2002       Impact factor: 2.370

Review 3.  Metformin's contraindications should be contraindicated.

Authors:  James McCormack; Kevin Johns; Hugh Tildesley
Journal:  CMAJ       Date:  2005-08-30       Impact factor: 8.262

Review 4.  Metformin in patients with type 2 diabetes and kidney disease: a systematic review.

Authors:  Silvio E Inzucchi; Kasia J Lipska; Helen Mayo; Clifford J Bailey; Darren K McGuire
Journal:  JAMA       Date:  2014 Dec 24-31       Impact factor: 56.272

5.  Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes.

Authors:  Xiaodan Zhang; William S Harmsen; Teresa A Mettler; W Ray Kim; Rosebud O Roberts; Terry M Therneau; Lewis R Roberts; Roongruedee Chaiteerakij
Journal:  Hepatology       Date:  2014-07-31       Impact factor: 17.425

6.  The Association between Metformin Therapy and Lactic Acidosis.

Authors:  Isabelle H S Kuan; Ruth L Savage; Stephen B Duffull; Robert J Walker; Daniel F B Wright
Journal:  Drug Saf       Date:  2019-12       Impact factor: 5.606

Review 7.  Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated?

Authors:  A A Tahrani; G I Varughese; J H Scarpello; F W F Hanna
Journal:  BMJ       Date:  2007-09-08

8.  [Female patient with type 2 diabetes in coma with metabolic acidosis].

Authors:  T zur Nieden; T Conrad
Journal:  Internist (Berl)       Date:  2009-11       Impact factor: 0.743

9.  Impact of acute kidney injury on metformin-associated lactic acidosis.

Authors:  Yao-Ko Wen
Journal:  Int Urol Nephrol       Date:  2009-03-12       Impact factor: 2.370

Review 10.  Insulin resistance postburn: underlying mechanisms and current therapeutic strategies.

Authors:  Gerd G Gauglitz; David N Herndon; Marc G Jeschke
Journal:  J Burn Care Res       Date:  2008 Sep-Oct       Impact factor: 1.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.